GlassScriptPhysician profile
Julian Sosner
NPI 1356354088
$6,015.53
in general payments reported to CMS, 2019-2025
30 companies · $659 in 2025
The $659 reported for 2025 was more than what 83% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $538 · 2021: $972 · 2022: $539 · 2023: $402 · 2024: $2,214 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $1,764 · Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $1,764.00 |
| Food and Beverage | $1,510.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,844.33 | 2019-2025 | Relistor |
| Johnson & Johnson Health Care Systems INC. | $1,764.00 | 2024 | |
| Collegium Pharmaceutical, INC. | $390.90 | 2019-2025 | Xtampza |
| Nevro Corp. | $306.58 | 2019-2021 | |
| Boston Scientific Corporation | $296.87 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $169.69 | 2019-2021 | |
| Redhill Biopharma INC. | $143.49 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $136.44 | 2020-2021 | |
| Fidia Pharma USA INC. | $118.02 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $100.04 | 2019-2021 | |
| Forte Bio-Pharma LLC | $97.73 | 2021-2023 | Prolate, Nalocet |
| Abbvie INC. | $88.69 | 2021-2024 | Botox |
| Teva Pharmaceuticals USA, INC. | $60.15 | 2022 | |
| Horizon Therapeutics Plc | $56.38 | 2019-2020 | |
| Pfizer INC. | $49.17 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45.46 | 2019 | |
| Medtronic USA, INC. | $41.38 | 2019-2020 | |
| Daiichi Sankyo INC. | $41.09 | 2019 | |
| Shionogi INC | $37.37 | 2019 | |
| Globus Medical, INC. | $34.66 | 2025 | Senza |
| Amgen INC. | $33.87 | 2021 | |
| Saluda Medical Americas, INC. | $25.62 | 2024 | Evoke |
| Valinor Pharma, LLC | $23.41 | 2025 | Movantik |
| Vertical Pharmaceuticals, LLC | $22.62 | 2019 | |
| Bioventus LLC | $20.70 | 2019 | |
| Depuy Synthes Sales INC. | $15.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.91 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.26 | 2023 | Kristalose |
| Indivior INC. | $12.09 | 2021 | |
| Medtronic, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Sosner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.